Author

krishnasharma

We are a market research Company

Analysts Predict a Neodymium Supply Crunch in 2015

A

With its demand significantly outpacing supply, Neodymium is expected to face a critical supply shortage in the coming years. As a decisive component of Neodymium-Iron-Boron (NdFeB) magnets, Neodymium plays an important role in a number of clean technology industries such as electric bicycles, hybrid cars, wind turbines, hard disk drives and a number of other energy efficient appliances. IMARC...

China’s Rare Earth Dominance

C

China currently has a monopoly over the global rare earth elements market accounting for 97% of the global production and 50% of the global reserves. In a language referring to the energy crises of the seventies, former Chinese leader Deng Xiaoping had stated in a 1992 speech, “the Middle East has its oil, and China has rare earth.   Key Aspects Analyzed in this Report: Understanding...

Raw Materials Supply Shortage Looms Over the Future Growth of Rare Earth Based Magnets

R

A new report from IMARC Group expects an exponential growth in the demand of rare earth based magnets in the coming years. A supply shortage of key raw materials, however, may jeopardize the growth of this entire industry. Rare earth based magnets represent the world’s strongest permanent magnets. These magnets enable a higher efficiency and motor power, and at the same time significantly reduce...

Sales of Diabetes Drugs to Witness Robust Growth in Emerging Markets

S

New studies released by IMARC Group suggests that the sales of diabetes drugs are expected to witness robust growth in major emerging markets. In its new therapy area insight series, IMARC Group, one of the world’s leading research and advisory firms, finds that the sales of both oral antidiabetics and insulin are expected to witness robust growth in major emerging markets. IMARC Group’s global...

Novel Classes to Drive Growth in Major European Oral Antidiabetic Markets

N

New studies on major European diabetes markets released by IMARC Group suggests that Novel classes will drive the growth of the Oral Antidiabetic markets in the coming years. In its new therapy area insight series – Diabetes, IMARC Group, one of the world’s leading research and advisory firms, finds that Novel classes such as DPP-IV Inhibitors, GLP-Agonists and SGLT inhibitors will play a...